1. Clinical Trial to Elucidate the Mechanism of Pulmonary Arterial Hypertension Targeting the Nitric Oxide Pathway

This Phase 1 clinical trial (NCT00098072), led by the NIH Clinical Center, was conducted to precisely elucidate the functional impairment of endothelial cells in patients with pulmonary arterial hypertension (PAH) and normal control subjects. Researchers measured changes in pulmonary artery pressure and acute hemodynamic responses in patients over 24 hours by administering gaseous nitric oxide (NO) and aerosolized nitrite. This was an attempt to identify the fundamental cellular dysfunction that causes pulmonary vasoconstriction and abnormal remodeling, rather than simply alleviating symptoms. This study also served as the foundational academic basis for INOpulse, a portable iNO delivery system developed by Bellerophon Therapeutics (BLPH).

2. Precision Biomarker Discovery Based on Omics Data

The researchers isolated circulating endothelial cells (CECs), endothelial progenitor cells (EPCs), and peripheral blood mononuclear cells (PBMCs) from the patients' blood and performed microarray and proteomics analyses. Through these advanced bioanalytical techniques, they derived individual genetic susceptibility and specific biomarker profiles, such as bone morphogenetic protein receptor type 2 (BMPR2) mutations. This paved the way for precision medicine by moving away from the conventional treatment focused on vascular constricting agents, allowing for the prediction and diagnosis of drug responsiveness in patients. The abundant multi-omics data obtained in this clinical trial has been utilized as a key target discovery database for subsequent new drug pipeline developers.

3. Differentiation from Competing Drugs and Clinical Value

The existing pulmonary arterial hypertension treatment market has been dominated by drugs such as Uptravi (Selexipag) and Opsumit (Macitentan) from Johnson & Johnson (JNJ), which temporarily dilate blood vessels. However, this NIH trial focused on restoring endothelial cell function through nitric oxide pathway activation, demonstrating a clear differentiation from existing standard treatments. In particular, Winrevair (Sotatercept) from Merck (MRK), which was approved by the FDA in March 2024, inhibits abnormal proliferation of pulmonary vascular cells and is expected to achieve $1.4 billion in sales in 2025, becoming a blockbuster drug. This clearly demonstrates the commercial impact of endothelial cell mechanism research. As such, the basic clinical results that directly repair cell-level damage are becoming milestones in the development of next-generation therapies.

4. Global Market Paradigm Shift and Investment Prospects

The global pulmonary arterial hypertension market is expected to reach approximately $7.3 billion to $9.2 billion by 2025-2026, with an annual growth rate of more than 5%, and is expected to exceed $11 billion in the mid-2030s, making it a highly attractive area for investment. Although this NIH trial was a single-institution, academic Phase 1 trial, Ikaria, which had related inhaled nitric oxide technology, was acquired by Mallinckrodt (MNK) for $2.3 billion in 2015, serving as a catalyst for major deals. Although Bellerophon Therapeutics' INOpulse failed in late-stage clinical trials, research on developing new drugs targeting endothelial cells and the nitric oxide pathway in the field of pulmonary arterial hypertension continues to attract ongoing interest and funding from venture capital (VC) and global pharmaceutical companies (Big Pharma).